It started as a diabetes injection. Then it became the world's most talked-about weight-loss drug. Now it's being tested for liver disease, addiction, and Alzheimer's. The story of semaglutide is really a story about how medicine changes its mind.
From Diabetes Drug to Cultural Phenomenon
When the FDA first approved semaglutide — as Ozempic, a once-weekly injection for type 2 diabetes — back in 2017, it was a meaningful but unremarkable advance in a crowded therapeutic class. A glucagon-like peptide-1 (GLP-1) receptor agonist, it worked by mimicking a hormone the gut naturally releases after eating, stimulating insulin secretion, suppressing glucagon, and slowing gastric emptying. Good drug. Filed and forgotten by most people outside endocrinology.
Then the weight-loss data came in. And nothing has been the same since.
By 2026, semaglutide has become arguably the most consequential pharmaceutical story of the decade — not because of any single breakthrough, but because of a relentless accumulation of evidence across conditions nobody originally expected it to touch. New pill formulations. Higher-dose injections. Approvals for liver disease. Signals in addiction medicine. A high-profile failure in Alzheimer's that still managed to leave important questions open. The drug keeps expanding, and so does our understanding of what GLP-1 receptors actually do in the body.
What's Been Approved: A Flurry of Decisions in 2025–2026
The pace of regulatory activity around semaglutide over the past eighteen months has been extraordinary.
The Wegovy Pill: A New Era for GLP-1 Access
Perhaps the single biggest development for patients has been the arrival of oral semaglutide for weight management. The FDA approved Wegovy in pill form in late 2025, with Novo Nordisk launching it in the US in early January 2026 at a list price of $149 per month. This marked the first oral GLP-1 receptor agonist approved for obesity — a milestone that matters enormously for the many patients who cannot tolerate injections or simply prefer a pill.
The approval was based on the OASIS 4 trial, a 64-week Phase 3 study. Participants taking oral semaglutide 25 mg once daily achieved approximately 16.6% mean weight loss when adherent to treatment, comparable to the injectable Wegovy 2.4 mg. Improvements were also seen in cardiometabolic risk factors including waist circumference, blood pressure, LDL cholesterol, and triglycerides.
Wegovy HD: Pushing the Dose Higher
In March 2026, the FDA approved a higher-dose injectable version — semaglutide 7.2 mg (Wegovy HD) — under the agency's new National Priority Voucher accelerated review framework. The Phase 3 STEP UP trial, enrolling 1,407 adults with obesity, demonstrated a mean weight loss of 20.7%, with 31.2% of participants achieving 25% or more body-weight reduction. This positions Wegovy HD as an escalation option for patients who don't respond adequately to the standard 2.4 mg dose, before they'd otherwise be referred for bariatric surgery.
Notably, a side effect called dysesthesia — abnormal skin sensations — occurred in 18.9% of patients on the 7.2 mg dose, compared to 4.9% on 2.4 mg and essentially zero on placebo. This is a new signal at this dose level and one that clinicians will be monitoring as the drug rolls out.
MASH: A Major New Frontier
In August 2025, the FDA granted accelerated approval to semaglutide for metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis — making it the first GLP-1 receptor agonist approved for this indication. MASH (formerly known as NASH) is a progressive liver disease closely linked to obesity and metabolic syndrome, and effective treatments have been desperately needed. This approval was supported by the ESSENCE trial, which showed significant improvements at 72 weeks. A long-term extension of that trial is ongoing, with outcomes data expected in 2029.
Cardiovascular and Kidney Protection
The cardiovascular case for semaglutide has become essentially ironclad. In October 2025, the FDA expanded the label for oral semaglutide to cover cardiovascular risk reduction in adults with type 2 diabetes at high risk — including, notably, patients without a prior heart attack or stroke, extending protection into the primary prevention space. This was supported by the SOUL trial, a large double-blind randomised controlled trial published in the New England Journal of Medicine.
On the kidney side, Ozempic (the diabetes-dose injection) received FDA approval as the first GLP-1 to reduce the risk of worsening kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease, supported by the Phase 3 FLOW trial.
The Alzheimer's Chapter: A Disappointing but Not Definitive Answer
The most anticipated — and ultimately most disappointing — semaglutide story of the past year was its failure in Alzheimer's disease.
The EVOKE and EVOKE+ trials were the largest ever conducted with a GLP-1 drug in Alzheimer's, enrolling approximately 1,800 people with early-stage disease (mild cognitive impairment and mild Alzheimer's) across multiple international sites. Results were first announced in November 2025 and then presented in full at the AD/PD 2026 International Conference on Alzheimer's and Parkinson's Diseases in March.
The outcome was unambiguous: oral semaglutide showed no difference from placebo at the primary endpoint of cognitive decline at two years, or on any of the secondary endpoints including activities of daily living, Mini-Mental State Examination scores, and progression from MCI to mild Alzheimer's.
This was a genuine disappointment for the neurodegenerative disease field, which had been watching GLP-1 research with real hope. Observational data had shown that GLP-1 receptor agonists appeared to reduce dementia incidence in people with diabetes, and preclinical studies suggested mechanisms that could plausibly affect Alzheimer's pathology. The EVOKE failure reminds us that observational associations and preclinical signals do not always survive the randomised trial.
That said, scientists have noted a few open questions. The trials used an oral formulation that may have achieved lower brain concentrations than an injectable version would. The participants were already symptomatic, which may mean intervention came too late. Several follow-on studies — including trials of injectable semaglutide in earlier or higher-risk populations — are continuing or in planning.
The Addiction Frontier: Surprising Signals
One of the most intriguing emerging areas for semaglutide is addiction medicine — and it's attracting serious scientific attention.
A Phase 2 randomised clinical trial published in JAMA Psychiatry in April 2025 found that once-weekly subcutaneous semaglutide significantly reduced alcohol craving, drinking quantity, and the number of heavy drinking days in adults with alcohol use disorder. A secondary finding was particularly striking: among participants who smoked at baseline, those on semaglutide had significantly greater reductions in cigarettes per day than those on placebo. No drug is currently approved for both alcohol use disorder and smoking cessation simultaneously.
The biological hypothesis is that GLP-1 receptors are expressed in reward pathways in the brain, particularly in areas associated with craving and reinforcement. If semaglutide blunts the reward signal for alcohol and possibly other substances, it could represent an entirely new mechanism for addiction treatment — distinct from existing pharmacotherapies like naltrexone or varenicline.
Multiple larger trials are now underway. The VA Office of Research and Development launched a Phase 3 randomised controlled trial in 2026 testing semaglutide specifically in veterans with alcohol use disorder. A separate European study (the SEMALCO trial) is investigating semaglutide in patients with alcohol use disorder and comorbid obesity. A pilot trial at the Ottawa Heart Institute is examining semaglutide for smoking cessation in people with diabetes.
None of these will report primary results before 2028 or 2029. But the early signals are real enough that addiction medicine specialists are paying close attention.
How It Works: A Reminder of the Biology
Semaglutide's expanding reach makes more sense when you understand how broadly GLP-1 receptors are distributed in the body. The hormone GLP-1 is not just a gut hormone — receptors are found in the pancreas, heart, kidneys, liver, brain, and in cells throughout the vascular system. This explains why a drug originally designed to improve blood sugar control also turns out to affect body weight, cardiovascular risk, liver inflammation, kidney function, and potentially brain reward circuits.
The core mechanisms include stimulating insulin secretion in response to food, suppressing glucagon release, slowing gastric emptying (which reduces appetite and food intake), and — at the molecular level — reducing inflammation and oxidative stress in multiple tissue types. The weight-loss effect itself appears to operate primarily through the central nervous system, reducing appetite and changing food reward signalling, which is also why addiction researchers are interested.
The Access Problem Hasn't Gone Away
For all the clinical progress, semaglutide's most persistent problem in 2026 remains access. Despite new formulations and increased manufacturing capacity, GLP-1 receptor agonists remain out of reach for millions of patients who could benefit from them.
The $149/month price point for oral Wegovy — positioned as an affordable entry point by Novo Nordisk — is still prohibitive for uninsured patients and those in healthcare systems that do not cover obesity treatment. Insurance coverage for weight-management indications remains inconsistent in the United States, even as the cardiovascular and kidney data have strengthened the medical case for broad use.
The shortage situation that characterised 2023–2024 has largely resolved as Novo Nordisk has scaled manufacturing, but affordability remains a structural barrier that no trial result can fix.
Where Things Stand
Semaglutide in 2026 is a drug in the middle of redefining what a "metabolic" medicine can do. Its approvals in obesity, heart disease, kidney disease, and liver disease represent a genuine expansion of what pharmacology can offer to conditions previously managed primarily through lifestyle or surgery.
The Alzheimer's failure is a reminder that GLP-1 receptor biology, for all its richness, is not magic — and that mechanistic plausibility does not guarantee clinical efficacy. The addiction signals are early but scientifically credible and deserve the rigorous trials they're now receiving.
The next two years will bring results from ongoing trials in heart failure with preserved ejection fraction, peripheral artery disease, and multiple addiction indications. If even a fraction of these succeed, the drug's footprint — already remarkable — will expand further still.
What began as a better diabetes injection has become something closer to a broad metabolic and systemic medicine. That transformation isn't complete. But it's hard to argue it isn't real.